Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC-are we making progress?

被引：2
|
作者：
Fenchel, Klaus [1 ,2 ]
Dale, Stephen P. [3 ]
Dempke, Wolfram C. M. [3 ,4 ]
机构：
[1] Med Sch Hamburg MSH, Hamburg, Germany
[2] Praxisklin Saalfeld Saale, Saalfeld, Germany
[3] Kyowa Kirin Pharmaceut Dev Ltd, Galashiels, Scotland
[4] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadern, Haematol & Oncol, Munich, Germany
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2016年 / 5卷 / 04期
关键词：
RANDOMIZED CONTROLLED-TRIAL; MUTANT LUNG-CANCER; 1ST-LINE TREATMENT; PHASE-3; TRIAL; DOUBLE-BLIND; OPEN-LABEL; CHEMOTHERAPY; GEFITINIB; AFATINIB; ADENOCARCINOMA;
D O I：
10.21037/tlcr.2016.07.01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：373 / 376
页数：4
相关论文
共 50 条
  • [41] Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic
    Skrickova, J.
    Chloupkova, R.
    Bortlicek, Z.
    Pesek, M.
    Kolek, V.
    Hejduk, K.
    Koubkova, L.
    Cernovska, M.
    Krejci, J.
    Zemanova, M.
    Havel, L.
    Roubec, J.
    Hrnciarik, M.
    Salajka, F.
    Coupkova, H.
    Satankova, M.
    Benejova, A.
    Grygarkova, I.
    Opalka, P.
    Sixtova, D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2135 - S2135
  • [42] Timing of angiotensin system inhibitor use and overall survival in patients on tyrosine kinase inhibitors for renal cell carcinoma
    Lam, Anthony P.
    Allen, John
    Srinivas, Sandy
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Consolidation EGFR-Tyrosine Kinase Inhibitor (TKI)vs. Durvalumab vs. Observation in Unresectable EGFRMutant Stage III NSCLC
    Nassar, A. H.
    Adib, E.
    Kaldas, D.
    Feng, J.
    AbuAli, T.
    Aredo, J.
    Fitzgerald, B.
    Bar, J.
    Thummalapalli, R.
    Parikh, K.
    Whitaker, R.
    Chen, L.
    Harris, J.
    Ayanambakkam, A.
    Farid, S.
    Owen, D.
    Sharp, J.
    Velazquez, A. I.
    Ragavan, M.
    D'aiello, A.
    Cheng, H.
    Piotrowska, Z.
    Wilgucki, M.
    Reuss, J. E.
    Patil, T.
    Nie, Y.
    Espinar, J. Baena
    Luders, H.
    Grohe, C.
    Sankar, K.
    Nagasaka, M.
    Ashara, Y. P.
    Kwiatkowski, D. J.
    Mak, R.
    Amini, A.
    Lobachov, A.
    Lin, J. J.
    Marron, T.
    Yu, H.
    Neal, J. W.
    Wakelee, H. A.
    Shepherd, F. A.
    Dilling, T. J.
    Gray, J. E.
    Naqash, A. R.
    Goldberg, S. B.
    Kim, S. Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S161 - S161
  • [44] EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Otsuka, K.
    Hata, A.
    Kato, R.
    Takeshita, J.
    Okuda, C.
    Kaji, R.
    Masago, K.
    Fujita, S.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2014, 25
  • [45] A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients
    Hida, T.
    Nishino, M.
    Yoh, K.
    Asato, T.
    Kitagawa, T.
    Zhang, S.
    Mehta, M.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S981 - S981
  • [46] CML Patients Show Sperm Alterations At Diagnosis That Are Not Improved On Tyrosine Kinase Inhibitor Treatment
    Nicolini, Franck E.
    Huguet, Francoise
    Labussiere-Wallet, Helene
    Guillermin, Yann
    Etienne, Madeleine
    Fort, Marie-Pierre
    Tigaud, Isabelle
    Hayette, Sandrine
    Morisset, Stephane
    Sobh, Mohamad
    Barraco, Fiorenza
    Michallet, Mauricette
    Daudin, Myriam
    Soula, Volcy
    d'Estaing, Sandrine Giscard
    Etienne, Gabriel
    BLOOD, 2012, 120 (21)
  • [47] A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naive Patients with Advanced NSCLC
    Lisberg, A.
    Hunt, J.
    Reese, N.
    Wang, T.
    Coluzzi, P.
    Spiegel, M.
    Bornazyan, K.
    Carroll, J.
    Madrigal, J.
    Ledezma, B.
    Mendenhall, M.
    Bui, J.
    Lu, H.
    Cummings, A.
    Noor, Z.
    Goldman, J. W.
    Garon, E.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1805 - S1805
  • [48] FREQUENT BASELINE EGFR MUTATION T790M IN CYTOLOGICAL SPECIMENS OF TYROSINE KINASE INHIBITOR (TKI) NAIVE ADENOCARCINOMA NSCLC PATIENTS
    Andarini, S. L.
    Zaini, J.
    Hudoyo, A.
    Hidayat, H.
    Widjajahakim, G.
    Utomo, A. R.
    RESPIROLOGY, 2016, 21 : 79 - 79
  • [49] p53 regulates Met tyrosine kinase inhibitor (TKI)-induced apoptosis in non small cell lung cancer (NSCLC) cells
    Jung, Hae-yun
    Joo, Hyun-Jung
    Kim, Yeul Hong
    CANCER RESEARCH, 2009, 69
  • [50] Alectinib Following Prior ALK Tyrosine Kinase Inhibitor (TKI) Therapy: Results from the US Expanded Access Program (EAP)
    Patel, J. D.
    Gadgeel, S. M.
    Ou, S. I.
    Le Maitre, A.
    Schulz, M.
    Liu, S.
    Zeaiter, A.
    Balas, B.
    Gupta, R.
    Shaw, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1573 - S1573
12345